Neumora Therapeutics, Inc. - 10-Q Filing
Neumora Therapeutics reports Q3 2025 financial results including research and development expenses and updates on licensing agreements.
Tickers: $NMRA
Neumora Therapeutics reports Q3 2025 financial results including research and development expenses and updates on licensing agreements.
Tickers: $NMRA